Qingfeng Ma

Qingfeng Ma


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Translational Stroke Research
Verified
Journal Article
Open access
PDF file
JLJiamin Li
Jiamin Li
ZWZixin Wang
Zixin Wang
JLJiameng Li
Jiameng Li
HZHaiping Zhao
Haiping Zhao
QMQingfeng Ma
Qingfeng Ma
Stroke in China is distinguished by its high rates of morbidity, recurrence, disability, and mortality. The ultra-early administration of rtPA is essential for restoring perfusion in acute ischemic stroke, though it concurrently elevates the risk of hemorrhagic transformation. High-mobility group box 1 (HMGB1) emerges as a pivotal player in neuroinflammation after brain ischemia and ischemia–reperfusion. Released passively by necrotic cells and actively secreted, including direct secretion of HMGB1 into the extracellular space and packaging of HMGB1 into intracellular vesicles by immune cells, glial cells, platelets, and endothelial cells, HMGB1 represents a prototypical damage-associated molecular pattern (DAMP). It is intricately involved in the pathogenesis of atherosclerosis, thromboembolism, and detrimental inflammation during the early phases of ischemic stroke. Moreover, HMGB1 significantly contributes to neurovascular remodeling and functional recovery in later stages. Significantly, HMGB1 mediates hemorrhagic transformation by facilitating neuroinflammation, directly compromising the integrity of the blood–brain barrier, and enhancing MMP9 secretion through its interaction with rtPA. As a systemic inflammatory factor, HMGB1 is also implicated in post-stroke depression and an elevated risk of stroke-associated pneumonia. The role of HMGB1 extends to influencing the pathogenesis of ischemia by polarizing various subtypes of immune and glial cells. This includes mediating excitotoxicity due to excitatory amino acids, autophagy, MMP9 release, NET formation, and autocrine trophic pathways. Given its multifaceted role, HMGB1 is recognized as a crucial therapeutic target and prognostic marker for ischemic stroke and hemorrhagic transformation. In this review, we summarize the structure and redox properties, secretion and pathways, regulation of immune cell activity, the role of pathophysiological mechanisms in stroke, and hemorrhage transformation for HMGB1, which will pave the way for developing new neuroprotective drugs, reduction of post-stroke neuroinflammation, and expansion of thrombolysis time window.

14 August 2020 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
HZHaiping Zhao
Haiping Zhao
FLFangfang Li
Fangfang Li
YHYuyou Huang
Yuyou Huang
SZSijia Zhang
Sijia Zhang
LLLingzhi Li
Lingzhi Li
YLYumin Luo
Yumin Luo
Background: An imbalance between circulating neuroprotective and neurotoxic T cell subsets leads to poor prognosis in acute ischaemic stroke (AIS). Preclinical studies have indicated that the soluble form of the interleukin-2 receptor α (sIL-2Rα)-IL-2 complex regulates T cell differentiation. However, the association between sIL-2Rα levels and AIS remains unclear.Methods: A total of 201 first-ever AIS patients within 24 h after stroke onset and 76 control subjects were recruited. The National Institutes of Health Stroke Scale (NIHSS) score and 3-month functional outcome (modified Rankin Scale [mRS] score) at admission were assessed. Plasma sIL-2Rα and IL-2 levels at admission were measured. Prognostic significance was identified by using univariate and multivariate logistic regression analyses.Results: Patients with poor functional outcomes at 3 months had significantly higher levels of sIL-2Rα and lower levels of IL-2 than patients with good outcomes. Moreover, sIL-2Rα levels showed a strong positive correlation with NIHSS and mRS scores (p< 0.0001), whereas IL-2 levels were negatively correlated with mRS scores (p< 0.01). Univariate analyses showed that higher sIL-2Rα and IL-2 levels were associated with an increased and reduced risk of unfavourable outcomes, respectively. After adjusting for confounding variables, the sIL-2Rα level remained independently associated with an increased risk of an unfavourable outcome, and adding sIL-2Rα levels to the conventional risk factor model significantly improved risk reclassification (net reclassification improvement 17.56%,p= 0.003; integrated discrimination improvement 5.78%,p =0.0003).Conclusions: sIL-2Rα levels represent a novel, independent prognostic marker that can improve the currently used risk stratification of AIS patients. Our findings also highlight that elevated plasma sIL-2Rα and IL-2 levels manifested opposite correlations with functional outcome, underlining the importance of IL-2/IL-2R autocrine loops in AIS.

28 June 2024 in Neuroscience
Verified
Journal Article
Closed access
JFJunfen Fan
Junfen Fan
LZLiyuan Zhong
Liyuan Zhong
FYFeng Yan
Feng Yan
XLXue Li
Xue Li
LLLingzhi Li
Lingzhi Li
YLYumin Luo
Yumin Luo

31 July 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LZLiyuan Zhong
Liyuan Zhong
ZXZixian Xie
Zixian Xie
ZHZiping Han
Ziping Han
JFJunfen Fan
Junfen Fan
RWRongliang Wang
Rongliang Wang
YLYumin Luo
Yumin Luo
Acute ischemic stroke (AIS) is a cerebrovascular disease that seriously affects the physical and mental health and quality of life of patients. However, there is a lack of reliable prognostic prediction methods. The main objective of this study was to investigate the prognostic value of long non-coding RNA (lncRNA) H19 in lymphocytes of patients with AIS, and to construct a prognostic prediction model for AIS including lncRNA H19 in lymphocytes, which would provide new ideas for the prognostic evaluation of AIS. Poor prognosis was defined when the patient’s modified Rankin scale (mRS) score at 3 months after AIS onset was greater than 2. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the level of lncRNA H19 in lymphocytes. Spearman correlation analysis revealed a positive correlation between lncRNA H19 and mRS score at 3 months after AIS onset (r = 0.1977, p = 0.0032), while lncRNA H19 was negatively correlated with white blood cells counts, lymphocytes counts, and neutrophils counts. Logistic regression analysis identified lncRNA H19 as an independent predictor of poor prognosis (OR = 3.062 [1.69–5.548], p < 0.001). Moreover, a nomogram prediction model incorporating lncRNA H19 in lymphocytes demonstrated effective discrimination, calibration, and clinical applicability in predicting AIS outcomes. The findings suggest that lncRNA H19 in lymphocytes could be a valuable prognostic indicator and a potential pharmacological target for AIS patients, and might be a novel pathway for enhanced prognostic evaluation and targeted therapeutic strategies.

11 June 2026 in Cellular and Molecular Neurobiology
Verified
Journal Article
Open access
LLLingzhi Li
Lingzhi Li
ZHZiping Han
Ziping Han
TSTong Shen
Tong Shen
ZYZhenhong Yang
Zhenhong Yang
JFJunfen Fan
Junfen Fan
YLYumin Luo
Yumin Luo
T-lymphokine-activated killer-cell-originated protein kinase (TOPK), was widely overexpressed in various malignant tumors, and played critical roles in their growth, differentiation and metastasis. However, its levels and potential clinical significance in acute ischemic stroke (AIS) was unknown. We detected the plasma TOPK protein level and mRNA level of neutrophilic TOPK in AIS patients using ELISA and RT-PCR, and analyzed their association with functional outcomes statistically. Among 330 patients with AIS, plasma TOPK concentrations differed significantly between patients present with excellent outcomes or not at 3 months. Plasma TOPK ≥ 69.95 pg/mL independently predicted excellent functional outcomes. In the subgroup of patients received rt-PA treatment, patients with TOPK ≥ 69.95 pg/ml also predicted excellent functional outcomes. Addition of plasma TOPK to clinical predictors for excellent outcomes post AIS as well as outcomes after rt-PA treatment improved their reclassification and discrimination. Although TOPK mRNA levels were significantly elevated in the neutrophils of AIS patients, no significant predictive value was observed for excellent outcomes. Conclusively, higher plasma TOPK levels (especially TOPK ≥ 69.95 pg/ml) might emerge as a prognostic indicator for the 3-month excellent functional outcomes post AIS and possessed predictive value in identifying patients with 3-month excellent functional outcomes after rt-PA treatment.